Riociguat

Riociguat
Clinical data
Trade names	Adempas
Other names	BAY 63-2521
AHFS/Drugs.com	Monograph
License data	US DailyMed: Riociguat;
Pregnancy; category	AU: X (High risk);
Routes of; administration	By mouth
ATC code	C02KX05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	94%
Protein binding	95%
Metabolism	CYP1A1, CYP3A4, CYP2C8, CYP2J2
Metabolites	N-desmethylriociguat (active), glucuronide (inactive)
Elimination half-life	12 h (patients); 7 h (healthy people)
Excretion	33–45% via kidney,; 48–59% via bile duct
Identifiers
	IUPAC name Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate;
CAS Number	625115-55-1 ;
IUPHAR/BPS	5257;
DrugBank	DB08931 ;
ChemSpider	9479719 ;
UNII	RU3FE2Y4XI;
KEGG	D09572 ;
ChEBI	CHEBI:76018 ;
CompTox Dashboard (EPA)	DTXSID50978109 ;
ECHA InfoCard	100.169.606
Chemical and physical data
Formula	C20H19FN8O2
Molar mass	422.424 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c14ncccc4c(-c(nc2N)nc(N)c2N(C)C(=O)OC)nn1Cc3ccccc3F;
	InChI InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26) ; Key:WXXSNCNJFUAIDG-UHFFFAOYSA-N ;
	(what is this?) (verify)

Riociguat, sold under the brand name Adempas, is a medication by Bayer that is a stimulator of soluble guanylyl cyclase (sGC). It is used to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of the class of sGC stimulators.^[4] The drug has a half-life of 12 hours and will decrease dyspnea associated with pulmonary arterial hypertension.

It is available as a generic medication.^[5]

^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
^ "Adempas EPAR". European Medicines Agency (EMA). 20 December 2007. Retrieved 10 August 2024.
^ Cite error: The named reference Drugs.com was invoked but never defined (see the help page).
^ "Background Riociguat". Bayer HealthCare. Archived from the original on 18 July 2011. Retrieved 15 December 2009.
^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

[1] "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

[2] "Adempas EPAR". European Medicines Agency (EMA). 20 December 2007. Retrieved 10 August 2024.

[Drugs.com-3] Cite error: The named reference Drugs.com was invoked but never defined (see the help page).

[TS2-4] "Background Riociguat". Bayer HealthCare. Archived from the original on 18 July 2011. Retrieved 15 December 2009.

[5] "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

[1]

[2]

[3]

[4]

[5]